MacroGenics, Inc. (MGNX)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 22.2M | 72.8M | 41.2M | 20.8M |
| Gross Profit | 13.3M | 61.2M | 31.1M | 11.2M |
| Operating Income | -36.8M | 18.6M | -12.1M | -33.4M |
| Net Income | -36.3M | 16.8M | -14.2M | -36.8M |
| Diluted EPS | $-0.57 | $0.27 | $nan | $-0.58 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 150.0M | 58.7M | 150.0M | 149.5M |
| Gross Profit | 142.6M | 50.5M | 137.7M | 113.5M |
| Operating Income | -121.4M | -168.2M | -110.6M | -72.8M |
| Net Income | -119.8M | -9.1M | -67.0M | -74.6M |
| Diluted EPS | $-1.95 | $-0.15 | $-1.07 | $nan |